Biochemical recurrence occurs in >20% of treated prostate cancer patients, mainly due to metastatic disease (>80%). In the multicenter clinical study ADOPT, 280 men with oligo-recurrent prostate cancer from 10 participating hospitals in the Netherlands are randomized to receive standard metastasis-targeted radiotherapy or metastasis-targeted radiotherapy in combination with 6 months of ADT. Biomaterial from eligible ADOPT patients will be used to establish the ADOPT biobank. Patients eligible for the ADOPT study will be asked to consent to blood collection prior to treatment and during 6 and 12 month follow-up. The ADOPT biobank plans to use new technology to identify and validate circulating tumor DNA (ctDNA) and extracellular vesicle (EV) biomarker. These will then be used as predictive and prognostic tools to improve the timing of clinical treatment and to more accurately monitor treatment response.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Farewell Dorine Swinkels
1 September 2026On Friday, September 4th, 2026, Dorine Swinkels will retire as Professor of Experimental Clinical Chemistry at Radboudumc. She is also leaving the Radboud Biobank.
go to page
Greening Radboud Biobank – reduction number of aliquots in storage for future initiatives
1 September 2026Like LUMC and NKI, the Radboud Biobank will also store fewer aliquots per collection tube.
go to page
Effect of Fit & Funding on external invoices
1 September 2026The Radboud Biobank not only manages issuances and projects for Radboudumc but also provides external services. The Radboud Biobank invoices the external organization for these services.
go to page
New link between iLES and Castor EDC connects clinical data and biobank material
1 September 2026The Biobank Information Management System, iLES, is now linked to Castor EDC. This development was realized within a KWF-funded project.
go to page
Radboud Biobank's 2025 annual report
3 March 2026The Radboud Biobank's 2025 annual report is now available on request.
go to page
Aevai Health developed a virtual assistant
3 March 2026Aevai Health has developed Alva - a virtual assistant to engage research participants, which can support participants with health literacy, understanding research protocols, and with using measurement devices.
go to page